Degrasyn activates proteasomal-dependent degradation of c-Myc

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3912-3918

  Bartholomeusz, Geoffrey ^a   Talpaz, Moshe ^a,b   Bornmann, William ^a   Kong, Ling Yuan ^a   Donato, Nicholas J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; DEGRASYN; MYC PROTEIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG; WP 1130;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG STRUCTURE; FEMALE; GENE MAPPING; GENE TARGETING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; HELA CELLS; HUMANS; MELANOMA; MICE; MICE, NUDE; MULTIPLE MYELOMA; NITRILES; PEPTIDE MAPPING; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248597738     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4464     Document Type: Article

References (50)

1. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004;4:289-302.
2. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996;382: 511-7.
3. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76.
4. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A 2003;100:5313-8.
5. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992;61:809-60.
6. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56: 1-48.
7. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-16.
8. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-610.
9. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
10. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18.
11. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
12. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999;18:717-26.
13. Flinn EM, Busch CM, Wright AP. myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol 1998;18:5961-9.
14. 2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem 2004;279:5008-16.
15. Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25.
16. Gavine PR, Neil JC, Crouch DH. Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles. Oncogene 1999;18:7552-8.
17. Tworkowski KA, Salghetti SE, Tansey WP. Stable and unstable pools of Myc protein exist in human cells. Oncogene 2002;21:8515-20.
18. Chen L, Smith L, Accavitti-Loper MA, Omura S, Bingham Smith J. Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable? Arch Biochem Biophys 2000;374:306-12.
19. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Riol 2000;20:2423-35.
20. Herbst A, Salghetti SE, Kim SY, Tansey WP. Multiple cell-type-specific elements regulate Myc protein stability. Oncogene 2004;23:3863-71.
21. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003;11:1177-88.
22. von der Lehr N, Johansson S, Wu S, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003;11:1189-200.
23. Huang Z, Traugh JA, Bishop JM. Negative control of the Myc protein by the stress-responsive kinase Pak2. Mol Cell Biol 2004;24:1582-94.
24. Huang Z. Stress signaling and Myc downregulation: implications for cancer. Cell Cycle 2004;3:593-6.
25. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
26. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19: 6613-26.
27. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
28. Latil A, Vidaud D, Valeri A, et al. htert expression correlates with MYC over-expression I n human prostate cancer. Int J Cancer 2000;89:172-6.
29. Bonvini P, Nguyen P, Trepel J, Neckers LM. In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome. Oncogene 1998;16: 1131-9.
30. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71.
31. Ciechanover A, DiGiuseppe JA, Bercovich B, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 1991;88: 139-43.
32. Gross-Mesilaty S, Reinstein E, Bercovich B, et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci U S A 1998;95:8058-63.
33. Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997;22:383-7.
34. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22:3087-91.
35. Biroccio A, Amodei S, Antonelli A, Benassi B, Zupi G. Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem 2003;278:35693-701.
36. Pastorino F, Brignole C, Marimpietri D, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 2003; 9:4595-605.
37. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-30.
38. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem 2006;281:9238-50.
39. Sarid J, Halazonetis TD, Murphy W, Leder P. Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity. Proc Natl Acad Sci U S A 1987;84:170-3.
40. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene 1999;18:2942-54.
41. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993;5:56-61.
42. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10.
43. Hoang AT, Lutterbach B, Lewis BC, et al. A link between increased transforming activity of lymphomaderived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol 1995;15:4031-42.
44. 2 arrest. Mol Cell Biol 2006;26:4226-39.
45. Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 1986;20:361-84.
46. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
47. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
48. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
49. Wilson A, Murphy MJ, Oskarsson T, et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004;18: 2747-63.
50. Sklar MD, Prochownik EV. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 1991;51:2118-23.